featured
Pathological Response Following Neoadjuvant Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Lancet Oncol 2024 Nov 01;25(11)1465-1475, A D'Alessio, B Stefanini, J Blanter, B Adegbite, F Crowley, V Yip, S Slater, CAM Fulgenzi, C Celsa, GF Manfredi, M Pai, RD Goldin, SC Ward, MI Fiel, DH Shu, YY Su, A Cortellini, M Baretti, R Anders, M Yarchoan, C Hsu, TU Marron, DJ PinatoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.